{"id":"intermediate-dose-nadroparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL2109204","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nadroparin is derived from unfractionated heparin through chemical depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 4,000 and 6,000 Da. It potentiates antithrombin III-mediated inhibition of activated factor X (factor Xa) more than thrombin, providing anticoagulant activity with a favorable pharmacokinetic profile for subcutaneous administration. The intermediate dose formulation is used for thromboprophylaxis and treatment of thromboembolic disorders.","oneSentence":"Nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:20.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in surgical patients"},{"name":"Treatment of deep vein thrombosis"},{"name":"Treatment of pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1110},{"nctId":"NCT01542762","phase":"NA","title":"Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation","status":"COMPLETED","sponsor":"Suzanne C. Cannegieter, MD PhD","startDate":"2012-03","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1500},{"nctId":"NCT01542723","phase":"NA","title":"Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy","status":"COMPLETED","sponsor":"Suzanne C. Cannegieter, MD PhD","startDate":"2012-05","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1500},{"nctId":"NCT01164046","phase":"PHASE3","title":"Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2010-08","conditions":"Venous Thromboembolism, Neoplasms","enrollment":56},{"nctId":"NCT02295150","phase":"PHASE4","title":"Prophylaxis of Venous Thromboembolism After Bariatric Surgery","status":"UNKNOWN","sponsor":"Rijnstate Hospital","startDate":"2013-03","conditions":"Morbid Obesity, Thromboembolism, Bypass Complications","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["nadroparin","Fraxiparin"],"phase":"marketed","status":"active","brandName":"Intermediate dose nadroparin","genericName":"Intermediate dose nadroparin","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Thromboprophylaxis in surgical patients, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}